Ophthalmic Manifestations of Mpox: What Clinicians Need to Know 

Ophthalmic Manifestations of Mpox: What Clinicians Need to Know

The estimated time to complete this enduring material is 60 minutes.

TARGET AUDIENCE

This accredited continuing education activity is designed for frontline workers, physicians, nurses, and infection preventionists.  

EDUCATIONAL OBJECTIVES

At the conclusion of this enduring material, the participant should be better able to:

• Describe both common and rare ophthalmic findings in mpox, given the ongoing mpox outbreak and public health emergency.
• Discuss the recent data and relevance of mpox DNA in the tear film for patients and health care providers.
• Review IPC precautions for ophthalmic evaluation including source control, equipment handling/disinfection, and implications for HCWs.

METHOD OF PARTICIPATION

In order to receive a certificate of completion, you must complete these steps.

1. View the entire presentation,
2. Complete the post-test with a score of 2 out of 3 or better,
3. Complete the online evaluation,
4. Submit the Completion Attestation.

FACULTY

Gerami Seitzman, MD
Consultant: Dompé Pharmaceutical, Kedrion Biopharma, Tarsus Pharmaceutical

Steven Yehm, MD, FASRS
Consultant: Adverum, Alcon, Bausch and Lomb

The following faculty have nothing to disclose:

• Jessica Carag, DVM. MS
• Jean-Claude Mwanza, MD, MPH, PhD
• Placide Mbala-Kingebeni, MD, PhD, MPH, M.Sc
• Anna Quay Yaffee, MD, MPH*

*faculty and planning committee member

PLANNING COMMITTEE

The below planning committee members have nothing to disclose:

• Britton Clark, MPH, CNP
• Valeta Creason-Wahl, MMP
• Jocelyn Herstein, PhD, MPH
• Chimora Imonugo, MD, MPH
• Heidi Keeler, PhD, MSN/MBA, RN
• Benjamin Mattson, MS Ed
• Jason Noble, BA, BFA
• Renee Paulin, MSN, RN, CWOCN
• Brenda Ram, CMP, CHCP
• Katie Stern, MPH

FINANCIAL SUPPORT 

This program is funded by ASPR